Inverse benefit law
Inverse Benefit Law
The Inverse Benefit Law is a concept in pharmacology and healthcare policy that suggests the ratio of benefits to harm among patients taking new drugs tends to vary inversely with how extensively a drug is marketed[1]. The term was coined by Donald Light and Joel Lexchin in 2012.
Pronunciation
- Inverse: /ɪnˈvɜːrs/
- Benefit: /ˈbɛnɪfɪt/
- Law: /lɔː/
Etymology
The term "Inverse Benefit Law" is derived from the English words "inverse", "benefit", and "law". "Inverse" comes from the Latin inversus, the past participle of invertere, meaning 'turn upside down'. "Benefit" is from the Latin benefactum, from bene 'well' + factum, neuter past participle of facere 'do'. "Law" is from the Old English lagu, from the Old Norse lag, which means 'something laid down or fixed'.
Related Terms
See Also
References
- ↑ Light, Donald W.; Lexchin, Joel; Darrow, Jonathan J. (2013). "Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs". Journal of Law, Medicine & Ethics. 14 (3): 590–610.
External links
- Medical encyclopedia article on Inverse benefit law
- Wikipedia's article - Inverse benefit law
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski